Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(66.7%)
N/A
1(33.3%)
3Total
Phase 2(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01455116Phase 2Terminated

The Cooling And Surviving Septic Shock Study (CASS)

Role: lead

NCT01950936Phase 2Completed

Procalcitonin To Reduce Antibiotics in Chronic Obstructive Lung Disease (ProToCOLD)

Role: lead

NCT00271752Not ApplicableCompleted

The Procalcitonin and Survival Study

Role: lead

NCT00144638Completed

Procalcitonin Increase Identifies Critically Ill Patients at High Risk of Mortality

Role: lead

All 4 trials loaded